Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.
Wall Street investors, spurred on by Trump's pro-business agenda, could be ignoring real risks posed by the president.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback